EVALUATION IN MONKEYS OF CANDIDATE VACCINES FOR SIMIAN

最近在恒河猴中成功保护猴的报告 免疫缺陷病毒（SIV）感染，使用灭活的全病毒 疫苗，为预防艾滋病的疫苗有一天可能成为 现实（Desrosier et al. 1989 and Murphey-Corb et al. 1989）。 非人 感染SIV或人类逆转录病毒HIV-2的灵长类动物代表了 动物模型最有可能作出重大贡献的发展， 成功的艾滋病疫苗 本提案的目的是建立 SIV疫苗评估单位（SVEU），提供资源，以评估 候选逆转录病毒疫苗的部分或全部安全性和有效性 由国家过敏和传染病研究所提供 （NIAID）。 梅森研究所（MRI）将提供现代非人类 灵长类动物设施和非人类灵长类动物饲养的专业知识， 药 MRI将在美国进行一项科学的逆转录病毒研究计划， 病毒学，免疫学和临床病理学领域的要求， NIAID工作说明书和任何后续修改。 MRI感知到 这是一种合作关系，MRI研究团队将 提供实验设施、服务和科学投入 这是专门针对NIAID的疫苗合同目标。

Recent reports in rhesus monkeys of successful protection against simian immunodeficiency virus (SIV) infection, using inactivated whole virus vaccines, have provided hope that a vaccine against AIDS may someday be a reality (Desrosier et al. 1989 and Murphey-Corb et al. 1989). Non-human primates infected with SIV or the human retrovirus HIV-2 represent the animal models most likely to make major contributions to the development of a successful AIDS vaccine. The objective of this proposal is to establish a SIV Vaccine Evaluation Unit (SVEU) to provide a resource to assess the safety and efficacy, partial or complete, of candidate retroviral vaccines supplied by the National Institute of Allergy and Infectious Diseases (NIAID). Mason Research Institute (MRI) will provide modern non-human primate facilities and expertise in non-human primate animal husbandry and medicine. MRI will conduct a scientific retroviral research program in the fields of virology, immunology and clinical pathology as required by the NIAID Statement of Work and any subsequent modifications. MRI perceives this as a collaborative relationship in which the MRI research team will provide facilities, services, and scientific input to conduct experiments which specifically address vaccine contract goals of the NIAID.